EGFRvIII-Targeted Alpha Therapy for Precision Cancer Cell Destruction in GBM
Time: 4:00 pm
day: Conference Day 2
Details:
- What is targeted alpha therapy (TAT) and theranostics?
- Advantages of TAT for treatment of GBM
- Preclinical evaluation of an EGFRvIII-targeted alpha therapy in PDX models with varying degrees of BBB permeability
